United States Cardiology KOLs Fair-Market Value (FMV) Compensation Rates Report 2023: An Independent Reference for Negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs)

DUBLIN, July 31, 2023 /PRNewswire/ -- The "Fair-Market Value Compensation Rates for Cardiology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.

We present comprehensive fair-market value (FMV) data on hourly and half-day compensation rates for US-based Key Opinion Leaders (KOLs) in Cardiology.

This in-depth report provides valuable insights into six (6) activities and non-specific activities, along with four (4) levels of Thought Leader influences, including rare, international, national, and local.

Our defensible market-based rate data is derived directly from industry compensation paid to Healthcare Practitioners (HCPs) and Thought Leaders (KOLs), ensuring accuracy and reliability.

These FMV rates reports serve as a trusted reference, helping to foster compliant negotiations and align fee schedules with prevailing market conditions, positioning your organization competitively in the industry.

Establishing fair-market value compensation rates will:

• Reduce the external perception of inappropriate inducement and limit regulatory and compliance risks.
• Provide an independent reference for negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs).
• Refine and support the development of fee schedules that are aligned with market conditions.
• Competitively position the organization and support good business practices.

The data included in each report are an aggregate of collected data and not individual rates. In no event, companies and individuals who provided the data are identified to protect their identity.

Thought Leader Compensation US Cardiology Cardiology

Payments made to physicians and thought leaders have been under scrutiny for a few years and companies have been working to adjust their rates to level with industry standards.

Nothing in this study constitutes financial or legal advice and we provide the contents of the study for information purposes only. This study may not be lent, resold, hired out or otherwise disposed of by way of trade in any form of binding or cover other than that in which it is published, without the prior written consent of the publisher.

INSIGHT

Research shows that less than 25% of pharmaceutical organizations begin working and involving Key Opinion Leaders during or before the clinical phase. Most - 63% - wait during phases 2 and 3 to start exchanging with Thought Leaders.

Key Topics Covered:

• Use of the Publisher's Copyrighted Materials
• Research Methodology
• Definitions
• Therapeutic Area
• Thought Leader Levels
• Flat Rates
• Hourly Rates
• Flat Rates
• Advisory Board Lead
• Advisory Board Non-lead
• Consulting Scientific/Clinical Content
• Consulting Commercial Content
• Speaking Scientific/Clinical Content
• Speaking Commercial Content
• Other Activities
• Hourly Rates
• Advisory Board Lead
• Advisory Board Non-lead
• Consulting Scientific/Clinical Content
• Consulting Commercial Content
• Speaking Scientific/Clinical Content
• Speaking Commercial Content
• Other Activities

For more information about this report visit https://www.researchandmarkets.com/r/1bbgcm

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets